Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Monica M, Marcus"'
Autor:
Anna Reymer, Anders Karlsson, Anaswara Ashok, Emma Johnsson, Jessica Hägglund, Joseph D. Bruton, Roger Karlsson, Kent Jardemark, Sreesha P. Srinivasa, Monica M. Marcus, Niklas Ivarsson, Max Davidson, Alexandra Cavallin, Daniela Papadia, Maria-Nefeli Christakopoulou, Carolina Trkulja, Gavin D. M. Jeffries, Oscar Jungholm, Owe Orwar, Peder Svensson, Gabriella Willman
Publikováno v:
Science Advances
This newly developed biological probes/proteomics method yields functional antibodies targeting previously undruggable targets.
Several important drug targets, e.g., ion channels and G protein–coupled receptors, are extremely difficult to appr
Several important drug targets, e.g., ion channels and G protein–coupled receptors, are extremely difficult to appr
Autor:
Monica M. Marcus, Ai Moriyama, Masako Furutani, Mayako Yamazaki, Junko Yarimizu, Mayuko Okabe, Noriyuki Yamamoto, Katsuya Harada, Torgny H. Svensson
Publikováno v:
European Neuropsychopharmacology. 28:620-629
The 5-HT5A receptor is arguably the least understood 5-HT receptor. Despite widespread expression in human and rodent brains it lacks specific ligands. Our previous results suggest that 5-HT5A receptor antagonists may be effective against cognitive i
Recently, a single injection of the nitric oxide donor sodium nitroprusside (SNP) was found to induce a rapid and sustained antipsychotic effect in treatment-resistant schizophrenia (TRS). Moreover, a single i.p. injection of SNP in rats was found to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d10845c5e342f338a6556d3ce02d53
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-397780
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-397780
Autor:
Ninni Påhlsson, Monica M. Marcus, Kent Jardemark, Anna Malmerfelt, Björn Schilström, Annie Möller, Kristin Feltmann, Carl Björkholm, Åsa Konradsson-Geuken, Torgny H. Svensson
Publikováno v:
European Neuropsychopharmacology. 26:1401-1411
Nicotine has been found to improve cognition and reduce negative symptoms in schizophrenia and a genetic and pathophysiological link between the α7 nicotinic acetylcholine receptors (nAChRs) and schizophrenia has been demonstrated. Therefore, there
Autor:
Masako Furutani, Ai Moriyama, Torgny H. Svensson, Mayuko Okabe, Katsuya Harada, Noriyuki Yamamoto, Monica M. Marcus, Junko Yarimizu, Mayako Yamazaki
Publikováno v:
European Neuropsychopharmacology. 29:S414-S415
Publikováno v:
European Neuropsychopharmacology. 29:S424-S425
Autor:
Mayako, Yamazaki, Noriyuki, Yamamoto, Junko, Yarimizu, Mayuko, Okabe, Ai, Moriyama, Masako, Furutani, Monica M, Marcus, Torgny H, Svensson, Katsuya, Harada
Publikováno v:
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 28(5)
The 5-HT
Autor:
Monica M. Marcus, Anna Malmerfelt, Björn Schilström, Svante Nyberg, Torgny H. Svensson, Kent Jardemark, Carl Björkholm
Publikováno v:
European Neuropsychopharmacology. 23:709-720
Quetiapine alleviates both positive and negative symptoms as well as certain cognitive impairments in schizophrenia despite a low D2 receptor occupancy and may also be used as monotherapy in bipolar and major depressive disorder. The mechanisms under
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 39:143-148
A substantial number of patients with major depressive disorder (MDD) do not respond adequately to current antidepressant pharmacological treatments, which are all more or less based on a gradually increased enhancement of monoaminergic neurotransmis
Publikováno v:
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 27(4)
Brexpiprazole (Rexulti®), a novel D2/3 receptor (R) partial agonist, was recently approved as monotherapy for schizophrenia, demonstrating effectiveness against both positive and negative symptoms, and also approved as add-on treatment to antidepres